Clinical Trial

Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D

Study acronym: Lpad Lyumjev
Completed
View on ClinicalTrials.gov →
Summary
A randomized controlled trial of Control-IQ, assessing glycemic control (time-in-range 70-180 mg/dL) for Lyumjev insulin (in which the insulin settings have been determined using an experimental conversion factor) as compared to Humalog or Novolog (using optimized settings)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-21; most recent amendment 2026-03-20.
Status change: Recruiting → Completed 2026-03-20
Status change: Not Yet Recruiting → Recruiting 2025-07-24
Trial Details
NCT Number NCT06948760
Lead Sponsor Mark D. DeBoer, MD, MSc., MCR
Collaborators: University of Virginia
Conditions Type 1 Diabetes
Enrollment 11 participants
Start Date 2025-07-23
Primary Completion 2026-02-27 (estimated)
Study Completion 2026-03-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-25